A national study shows that multimodal prehabilitation significantly reduces complications in colorectal cancer surgery, improving outcomes for patients. Overall complication rates dropped from 37.8% to 30.1% in the prehabilitation group (odds ratio 0.71). Medical complications decreased from 24.6% to 15.4% (odds ratio 0.56). Length of hospital stay was reduced by 1 day, from 5 to […]
Author: STITCHES Newsletter
Neoadjuvant Chemo May Not Improve Survival in Early PDAC
Neoadjuvant chemotherapy’s benefit in early-stage pancreatic ductal adenocarcinoma is questionable due to bias in survival estimates. In a study of 13,466 patients, those receiving neoadjuvant chemotherapy showed initially longer median survival (33.4 vs. 25.7 months) but this disappeared after correcting for immortal time bias. Three robust statistical methods revealed no significant survival advantage for neoadjuvant […]
Study finds no link between hernia mesh and autoimmune disease
Mesh implantation during hernia repairs does not increase the risk of developing autoimmune diseases compared to surgeries without mesh. Incidence of new autoimmune disease was 1.1% for hernia patients and 1.5% for cholecystectomy controls, showing no statistically significant difference (p = 0.520). This finding challenges fears surrounding mesh use, which may influence patient decision-making and […]
Laparoscopic Approach Safe for Large Hepatocellular Tumors
Laparoscopic anterior-approach right posterior sectionectomy is a safe option for hepatocellular carcinoma tumors over 10 cm. Four patients with median tumor size of 11.5 cm underwent the procedure; all had negative margins. Median operative time was 524 minutes with minimal blood loss (80 ml) and no transfusions. This technique allows for secure transection without the […]
Fluorescence-Guided Remnant-Sparing Distal Pancreatectomy Shows Promise
Surgeons can safely perform a remnant-sparing distal pancreatectomy using fluorescence guidance for select patients with metachronous pancreatic cancer after Whipple procedure. The procedure was completed in 123 minutes with only 20 ml of blood loss. Post-op, the patient had a normal amylase level and was discharged by day 5 with no complications. This approach preserves […]
Survival Tied to Timely, Guideline-Concordant Care in Cancer
Optimal treatment timing significantly impacts survival in localized colon, lung, and pancreatic cancers. 68.7% of colon cancer, 70.6% of non-small cell lung cancer (NSCLC), and 22.6% of pancreatic cancer patients received optimal care. Patients receiving optimal care had much lower death risk: colon cancer HR 0.45, NSCLC HR 0.35, pancreatic cancer HR 0.46. Optimal care’s […]
Defining Ideal Outcomes for Distal Pancreatectomy
Surgeons now have a validated definition of a textbook outcome for distal pancreatectomy, which influences patient selection and post-operative management. Textbook outcomes include no readmissions or deaths within 90 days, length of stay below the 75th percentile, no major complications, and negative margins. In a study of 339 patients, only 46.3% achieved this outcome; major […]
Higher Morbidity in Robotic Pancreatoduodenectomy Conversion
Robotic pancreatoduodenectomy has greater postoperative complication risks than laparoscopic, especially after conversion. Major morbidity rates are 49% in robotic (rpd) versus 31% in laparoscopic (lpd) after conversion (p=0.021). Conversion required in 12% of cases, with no significant difference between robotic (12%) and laparoscopic (14%). Surgeons should assess conversion risks when choosing robotic methods, emphasizing structured […]
Analgesia Revolution: Rectus Sheath vs. Epidural for Open Surgery
Rectus sheath catheters offer a safe pain management alternative to thoracic epidural analgesia, reducing complications and costs for open surgery patients. No significant difference in postoperative pain scores or opioid use between the two methods. Rectus sheath catheters cut the risk of hypotension by 60% and lower costs between $500 and $6632 per case. These […]
Missing Data Biases Outcomes in Cancer Treatment Studies
Non-cancer center patients have worse survival outcomes and more missing data. Missing data prevalence was significantly higher at non-cancer centers (e.g., NSCLC: 42% vs 13% at cancer centers). Three-year overall survival was lower for patients with missing data across all cancers (e.g., breast: 63% vs 81%). Consider the implications of missing data in decision-making and […]